Walleye Capital LLC Takes Position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Walleye Capital LLC purchased a new stake in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 69,479 shares of the company’s stock, valued at approximately $134,000. Walleye Capital LLC owned about 0.09% of Tenaya Therapeutics as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. FMR LLC lifted its stake in shares of Tenaya Therapeutics by 1.9% in the 3rd quarter. FMR LLC now owns 1,345,938 shares of the company’s stock valued at $2,598,000 after purchasing an additional 25,503 shares during the last quarter. abrdn plc acquired a new position in shares of Tenaya Therapeutics in the 3rd quarter valued at $1,063,000. SG Americas Securities LLC acquired a new position in shares of Tenaya Therapeutics in the 3rd quarter valued at $49,000. Algert Global LLC acquired a new position in shares of Tenaya Therapeutics in the 2nd quarter valued at $74,000. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Tenaya Therapeutics by 43.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock valued at $72,000 after purchasing an additional 7,000 shares during the last quarter. Institutional investors and hedge funds own 90.54% of the company’s stock.

Tenaya Therapeutics Stock Up 2.2 %

Shares of Tenaya Therapeutics stock opened at $3.66 on Thursday. Tenaya Therapeutics, Inc. has a 52-week low of $1.61 and a 52-week high of $7.01. The company has a 50 day moving average of $2.40 and a 200 day moving average of $2.79. The company has a market capitalization of $289.95 million, a P/E ratio of -2.54 and a beta of 2.71.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.07. As a group, research analysts anticipate that Tenaya Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Canaccord Genuity Group reissued a “buy” rating and set a $16.00 target price on shares of Tenaya Therapeutics in a research note on Friday, October 18th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Tenaya Therapeutics in a research report on Monday, November 25th. Chardan Capital lowered their price objective on shares of Tenaya Therapeutics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Piper Sandler reissued an “overweight” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Finally, Leerink Partners reissued an “outperform” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $17.33.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.